CBM: Cambrex Corporation - Summary | Jitta

Cambrex Corporation

NYSE:CBM

Notice
Stock data is unavailable or the company’s delisted.
Price
$59.99
Loss Chance
58.4%
5.18JITTA SCORE
86.52%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (53)
Recent Business Performance (20)
Financial Strength (89)
Return to Shareholders (37)
Competitive Advantage (84)
Jitta Signs
Revenue and EarningConsistent
Operating MarginDeclined
Recent Business PerformanceEarning decline 11.35% in the last year
Key Stats
Jitta Score
Jitta Line
5.18
86.52%
Life Sciences Tools and Services
7.24
177.56%
4.35
87.69%
3.52
106.67%
COMPANY DESCRIPTION
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey. As of December 4, 2019, Cambrex Corporation was taken private.